Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients

The expression of mesothelin correlates with a poor prognosis in patients with breast cancer. Since mesothelin plays a role in cancer metastasis in association with CA125, we herein examined the expression of mesothelin and CA125, and the clinicopathological meaning and prognosis of the co-expressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Einama, Takahiro, Yamagishi, Yoji, Takihata, Yasuhiro, Suzuki, Takafumi, Yamasaki, Tamio, Hirose, Yuichi, Kobayashi, Kazuki, Yonamine, Naoto, Fujinuma, Ibuki, Tsunenari, Takazumi, Koga, Makiko, Ishibashi, Yusuke, Nagata, Ken, Shiraishi, Takehiro, Nakazawa, Akiko, Iwasaki, Toshimitsu, Shinto, Eiji, Kato, Kimi, Sato, Kimiya, Ueno, Hideki, Kishi, Yoji, Tsuda, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555316/
https://www.ncbi.nlm.nih.gov/pubmed/34715925
http://dx.doi.org/10.1186/s40364-021-00335-3
_version_ 1784591954209669120
author Einama, Takahiro
Yamagishi, Yoji
Takihata, Yasuhiro
Suzuki, Takafumi
Yamasaki, Tamio
Hirose, Yuichi
Kobayashi, Kazuki
Yonamine, Naoto
Fujinuma, Ibuki
Tsunenari, Takazumi
Koga, Makiko
Ishibashi, Yusuke
Nagata, Ken
Shiraishi, Takehiro
Nakazawa, Akiko
Iwasaki, Toshimitsu
Shinto, Eiji
Kato, Kimi
Sato, Kimiya
Ueno, Hideki
Kishi, Yoji
Tsuda, Hitoshi
author_facet Einama, Takahiro
Yamagishi, Yoji
Takihata, Yasuhiro
Suzuki, Takafumi
Yamasaki, Tamio
Hirose, Yuichi
Kobayashi, Kazuki
Yonamine, Naoto
Fujinuma, Ibuki
Tsunenari, Takazumi
Koga, Makiko
Ishibashi, Yusuke
Nagata, Ken
Shiraishi, Takehiro
Nakazawa, Akiko
Iwasaki, Toshimitsu
Shinto, Eiji
Kato, Kimi
Sato, Kimiya
Ueno, Hideki
Kishi, Yoji
Tsuda, Hitoshi
author_sort Einama, Takahiro
collection PubMed
description The expression of mesothelin correlates with a poor prognosis in patients with breast cancer. Since mesothelin plays a role in cancer metastasis in association with CA125, we herein examined the expression of mesothelin and CA125, and the clinicopathological meaning and prognosis of the co-expression of mesothelin and CA125 in breast cancer. Our results showed that among 478 patients, mesothelin and CA125 were co-expressed in 48 (10 %), mesothelin only in 75 (16 %), CA125 only in 217 (45 %), and neither in 234 (49 %). A high correlation was observed between the expression of mesothelin and CA125 (P =0.0004). The co-expression of mesothelin and CA125 correlated with poor patient relapse-free survival (RFS) (P = 0.0001) and was identified as an independent predictor of RFS by Cox’s multivariate analysis. In conclusion, this is the first to report the prognostic significance of the co-expression of mesothelin and CA125 in breast cancer. The co-expression of mesothelin and CA125 may be clinically useful for prognostication after surgical therapy in patients with breast cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-021-00335-3.
format Online
Article
Text
id pubmed-8555316
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85553162021-10-29 Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients Einama, Takahiro Yamagishi, Yoji Takihata, Yasuhiro Suzuki, Takafumi Yamasaki, Tamio Hirose, Yuichi Kobayashi, Kazuki Yonamine, Naoto Fujinuma, Ibuki Tsunenari, Takazumi Koga, Makiko Ishibashi, Yusuke Nagata, Ken Shiraishi, Takehiro Nakazawa, Akiko Iwasaki, Toshimitsu Shinto, Eiji Kato, Kimi Sato, Kimiya Ueno, Hideki Kishi, Yoji Tsuda, Hitoshi Biomark Res Letter to the Editor The expression of mesothelin correlates with a poor prognosis in patients with breast cancer. Since mesothelin plays a role in cancer metastasis in association with CA125, we herein examined the expression of mesothelin and CA125, and the clinicopathological meaning and prognosis of the co-expression of mesothelin and CA125 in breast cancer. Our results showed that among 478 patients, mesothelin and CA125 were co-expressed in 48 (10 %), mesothelin only in 75 (16 %), CA125 only in 217 (45 %), and neither in 234 (49 %). A high correlation was observed between the expression of mesothelin and CA125 (P =0.0004). The co-expression of mesothelin and CA125 correlated with poor patient relapse-free survival (RFS) (P = 0.0001) and was identified as an independent predictor of RFS by Cox’s multivariate analysis. In conclusion, this is the first to report the prognostic significance of the co-expression of mesothelin and CA125 in breast cancer. The co-expression of mesothelin and CA125 may be clinically useful for prognostication after surgical therapy in patients with breast cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-021-00335-3. BioMed Central 2021-10-29 /pmc/articles/PMC8555316/ /pubmed/34715925 http://dx.doi.org/10.1186/s40364-021-00335-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter to the Editor
Einama, Takahiro
Yamagishi, Yoji
Takihata, Yasuhiro
Suzuki, Takafumi
Yamasaki, Tamio
Hirose, Yuichi
Kobayashi, Kazuki
Yonamine, Naoto
Fujinuma, Ibuki
Tsunenari, Takazumi
Koga, Makiko
Ishibashi, Yusuke
Nagata, Ken
Shiraishi, Takehiro
Nakazawa, Akiko
Iwasaki, Toshimitsu
Shinto, Eiji
Kato, Kimi
Sato, Kimiya
Ueno, Hideki
Kishi, Yoji
Tsuda, Hitoshi
Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients
title Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients
title_full Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients
title_fullStr Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients
title_full_unstemmed Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients
title_short Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients
title_sort co-expression of mesothelin and ca125/muc16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555316/
https://www.ncbi.nlm.nih.gov/pubmed/34715925
http://dx.doi.org/10.1186/s40364-021-00335-3
work_keys_str_mv AT einamatakahiro coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT yamagishiyoji coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT takihatayasuhiro coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT suzukitakafumi coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT yamasakitamio coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT hiroseyuichi coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT kobayashikazuki coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT yonaminenaoto coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT fujinumaibuki coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT tsunenaritakazumi coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT kogamakiko coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT ishibashiyusuke coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT nagataken coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT shiraishitakehiro coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT nakazawaakiko coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT iwasakitoshimitsu coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT shintoeiji coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT katokimi coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT satokimiya coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT uenohideki coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT kishiyoji coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients
AT tsudahitoshi coexpressionofmesothelinandca125muc16isaprognosticfactorforbreastcancerespeciallyinluminaltypebreastcancerpatients

Ejemplares similares